Assessment of adult rat cardiac fibroblast viability following chronic sunitinib treatment

Calum J McMullen; Rachel A Wood; Margaret R Cunningham; Susan Currie

doi:10.1136/heartjnl-2019-SCF.13

Assessment of adult rat cardiac fibroblast viability following chronic sunitinib treatment

Calum J McMullen, Rachel A Wood, Margaret R Cunningham, Susan Currie

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

6 Citations (Scopus)

29 Downloads (Pure)

Abstract

The tyrosine kinase inhibitor sunitinib has dramatically improved cancer therapy in recent years however, this success has been marred by reports of associated cardiotoxicity. The effect of sunitinib on cardiac myocyte function has been extensively studied, yet little is known of wider ranging effects on cardiac non-myocytes. Cardiac fibroblasts (CF) are the most abundant cell type within the heart and are responsible for maintaining cardiac structure via extracellular matrix remodelling and for facilitating synchronised cardiac contraction. Here, we have investigated whether chronic sunitinib treatment adversely affects CF viability.

Original language	English
Pages (from-to)	A6-A7
Number of pages	2
Journal	Heart
Volume	105
Issue number	suppl 4
DOIs	https://doi.org/10.1136/heartjnl-2019-SCF.13
Publication status	Published - 1 May 2019
Event	14th British Society of Cardiovascular Magnetic Resonance Annual Meeting 2019 - Oxford, United Kingdom Duration: 26 Mar 2019 → 27 Mar 2019

Keywords

tyrosine kinase inhibitor
sunitinib
cardiac fibroblast

Access to Document

10.1136/heartjnl-2019-SCF.13

McMullen-etal-Heart-2019-Assessment-of-adult-rat-cardiac-fibroblastsAccepted author manuscript, 270 KBLicence: CC BY-NC 4.0

Cite this

@article{c70a41f1a145408fb01e1d96f9994e39,

title = "Assessment of adult rat cardiac fibroblast viability following chronic sunitinib treatment",

abstract = "The tyrosine kinase inhibitor sunitinib has dramatically improved cancer therapy in recent years however, this success has been marred by reports of associated cardiotoxicity. The effect of sunitinib on cardiac myocyte function has been extensively studied, yet little is known of wider ranging effects on cardiac non-myocytes. Cardiac fibroblasts (CF) are the most abundant cell type within the heart and are responsible for maintaining cardiac structure via extracellular matrix remodelling and for facilitating synchronised cardiac contraction. Here, we have investigated whether chronic sunitinib treatment adversely affects CF viability.",

keywords = "tyrosine kinase inhibitor, sunitinib, cardiac fibroblast",

author = "McMullen, {Calum J} and Wood, {Rachel A} and Cunningham, {Margaret R} and Susan Currie",

year = "2019",

month = may,

day = "1",

doi = "10.1136/heartjnl-2019-SCF.13",

language = "English",

volume = "105",

pages = "A6--A7",

journal = "Heart ",

issn = "1355-6037",

publisher = "BMJ Publishing Group",

number = "suppl 4",

note = "14th British Society of Cardiovascular Magnetic Resonance Annual Meeting 2019, BSCMR 2019 ; Conference date: 26-03-2019 Through 27-03-2019",

}

TY - JOUR

T1 - Assessment of adult rat cardiac fibroblast viability following chronic sunitinib treatment

AU - McMullen, Calum J

AU - Wood, Rachel A

AU - Cunningham, Margaret R

AU - Currie, Susan

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The tyrosine kinase inhibitor sunitinib has dramatically improved cancer therapy in recent years however, this success has been marred by reports of associated cardiotoxicity. The effect of sunitinib on cardiac myocyte function has been extensively studied, yet little is known of wider ranging effects on cardiac non-myocytes. Cardiac fibroblasts (CF) are the most abundant cell type within the heart and are responsible for maintaining cardiac structure via extracellular matrix remodelling and for facilitating synchronised cardiac contraction. Here, we have investigated whether chronic sunitinib treatment adversely affects CF viability.

AB - The tyrosine kinase inhibitor sunitinib has dramatically improved cancer therapy in recent years however, this success has been marred by reports of associated cardiotoxicity. The effect of sunitinib on cardiac myocyte function has been extensively studied, yet little is known of wider ranging effects on cardiac non-myocytes. Cardiac fibroblasts (CF) are the most abundant cell type within the heart and are responsible for maintaining cardiac structure via extracellular matrix remodelling and for facilitating synchronised cardiac contraction. Here, we have investigated whether chronic sunitinib treatment adversely affects CF viability.

KW - tyrosine kinase inhibitor

KW - sunitinib

KW - cardiac fibroblast

UR - https://heart.bmj.com/

U2 - 10.1136/heartjnl-2019-SCF.13

DO - 10.1136/heartjnl-2019-SCF.13

M3 - Meeting abstract

SN - 1355-6037

VL - 105

SP - A6-A7

JO - Heart

JF - Heart

IS - suppl 4

T2 - 14th British Society of Cardiovascular Magnetic Resonance Annual Meeting 2019

Y2 - 26 March 2019 through 27 March 2019

ER -

Assessment of adult rat cardiac fibroblast viability following chronic sunitinib treatment

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

22nd Scottish Cardiovascular Forum 2019

Cite this

Assessment of adult rat cardiac fibroblast viability following chronic sunitinib treatment

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Activities

22nd Scottish Cardiovascular Forum 2019

Cite this